SRRK
Scholar Rock Holding Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
56.50
▲ 1.25 (2.26%)
MARKET · —
Price
Open
56.06
Prev close
55.25
Day high
57.08
Day low
54.98
Volume
1.13M
Market cap
$6.88B
P/E (TTM)
—
52W range
27.07 – 58.49
Trailing performance
Returnvs SPY
1W
+7.58%
+8.9%
1M
+14.19%
+10.5%
3M
+18.40%
+15.3%
6M
+17.71%
+6.6%
YTD
+28.26%
+16.0%
1Y
+64.24%
+44.2%
3Y
+750.90%
+676.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$6.88B
Enterprise value$6.59B
Revenue (TTM)—
Gross profit$-207.41M
EBITDA$-404.88M
Net income$-408.59M
EPS (TTM)$-3.31
Free cash flow$-153.88M
Total cash$492.09M
Total debt$203.83M
Book value / share$2.09
Shares outstanding121.79M
Float104.09M
Short % of float18.14%
Dividend yield—
Beta (5Y)0.67
Valuation & profitability ratios
Trailing P/E—
Forward P/E-24.27
PEG ratio—
Price / sales—
Price / book27.07
EV / revenue—
EV / EBITDA-16.28
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-167.77%
Return on assets-58.82%
Debt / equity80.32
Current ratio7.02
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $33.19M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$377.94M | -$246.29M | -$165.79M | -$134.50M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$377.94M | -$246.29M | -$165.79M | -$134.50M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.84 | -0.84 | +0.3% |
| Mar 2026 | -0.78 | -0.83 | -6.3% |
| Dec 2025 | -0.88 | -0.88 | +0.3% |
| Sep 2025 | -0.84 | -0.90 | -7.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.83 | 12 | $70.00K | 0.0% |
| Next quarter | -0.73 | 15 | $5.59M | 0.0% |
| Current year | -3.12 | 12 | $5.76M | 0.0% |
| Next year | -2.56 | 16 | $147.94M | +2,470.1% |
Analyst targets & ownership
Mean target$60.38
High target$76.00
Low target$48.00
Implied upside6.86%
Analyst count16
ConsensusSTRONG BUY
Strong buy / Buy3 / 15
Hold0
Sell / Strong sell0 / 0
Held by insiders0.77%
Held by institutions117.50%
Institutions holding419
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+48.55K
Net buying
Buy transactions
8
137.67K shares
Sell transactions
10
89.12K shares
Net transactions
+18
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
935.31K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 1, 26 | PENG KATIE Director |
SELL | 5.45K | $293.40K | Direct |
| Jul 1, 26 | GILMAN MICHAEL Z Director |
SELL | 2.54K | $137.06K | Direct |
| Jul 1, 26 | BUROW KRISTINA M Director |
SELL | 3.05K | $164.06K | Direct |
| Jul 1, 26 | FLIER JEFFREY S. Director |
SELL | 3.05K | $164.49K | Direct |
| Jul 1, 26 | REED JOSHUA Director |
SELL | 3.05K | $164.07K | Direct |
| Jun 4, 26 | GILMAN MICHAEL Z Director |
STOCK | 6.84K | $0 | Direct |
| Jun 4, 26 | BUROW KRISTINA M Director |
STOCK | 6.84K | $0 | Direct |
| Jun 4, 26 | BRUDNICK RICHARD Director |
STOCK | 6.84K | $0 | Direct |
| Jun 4, 26 | FLIER JEFFREY S. Director |
STOCK | 6.84K | $0 | Direct |
| Jun 4, 26 | REED JOSHUA Director |
STOCK | 6.84K | $0 | Direct |
| Jun 4, 26 | AKKARAJU SRINIVAS Director |
STOCK | 6.84K | $0 | Direct |
| Jun 4, 26 | PENG KATIE Director |
STOCK | 6.84K | $0 | Direct |
| Apr 23, 26 | BUROW KRISTINA M Director |
CONVERSION | 89.80K | $820.32K | Direct |
| Apr 16, 26 | WOODS KEITH Chief Operating Officer |
SELL | 10.22K | $506.65K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AKKARAJU SRINIVAS |
Director | 6.93M | Stock Award(Grant) |
BACKSTROM JAY T |
Chief Executive Officer | 425.56K | Stock Award(Grant) |
BUROW KRISTINA M |
Director | 2.46M | Sale |
HALLAL DAVID L |
Chief Executive Officer | 1.84M | Sale |
HO JUNLIN |
General Counsel | 241.54K | Sale |
INVUS GLOBAL MANAGEMENT, LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
PARLAVECCHIO CARYN |
Officer | 169.09K | Sale |
SINHA VIKAS |
Chief Financial Officer | 619.86K | Sale |
VAISHNAW AKSHAY K |
Officer and Director | 630.54K | Sale |
WOODS KEITH |
Chief Operating Officer | 620.05K | Sale |
Moving averages & technicals
SMA 10
53.84
+4.94% from price
SMA 20
51.46
+9.80% from price
SMA 50
51.59
+9.52% from price
SMA 100
49.78
+13.50% from price
SMA 200
46.40
+21.76% from price
EMA 12
53.66
+5.30% from price
EMA 26
52.37
+7.89% from price
EMA 50
51.35
+10.02% from price
RSI (14)
62.7
Neutral
MACD (12,26,9)
1.29
Hist 0.64
ATR (14)
2.49
4.41% of price
Realised vol 30D
50.8%
Annualised
Bollinger upper
57.58
20, 2σ
Bollinger lower
45.33
20, 2σ
50 / 200 cross
Golden
51.59 vs 46.40
Trend bias
Above 200
+21.76%
Risk profile
Beta vs SPY
0.98
Less volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
50.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-31.9%
Peak to trough
Max drawdown 5Y
-88.7%
Peak to trough
ATR 14
2.49
4.41% of price
Beta (reported)
0.67
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.62
Call-heavy session
Put / call open interest
0.18
Positioning, not flow
Max pain
55.00
-2.7% from spot
ATM implied vol
58.5%
Nearest strike to spot
Skew (10% OTM)
-1.5%
Calls bid over puts
Call volume
61
Contracts, this expiry
Put volume
38
Contracts, this expiry
Heaviest call OI
60.00
3.33K contracts
Heaviest put OI
50.00
491 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Is Scholar Rock Holding (SRRK) Fairly Valued On Its Apitegromab Regulatory Progress?
Simply Wall St. · 3h ago
Scholar Rock (SRRK) Streamlines Apitegromab Filings After Catalent Shift Is Regulatory Strategy De-Risking The Story?
Simply Wall St. · 6h ago
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing
Stocktwits · 17h ago
Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says
MT Newswires · 19h ago
Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility
MT Newswires · 1d ago
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
Business Wire · 1d ago
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab
MarketBeat · 5d ago
Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks?
Insider Monkey · 8d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.